Diagnostics and therapeutics for an obstructive airway disease
AssigneeInterleukin Genetics, Inc.
InventorsGordon W. Duff, Francesco S. di Giovine, Peter J. Barnes, Samson Lim
Life of this patent
Estimating the term…
Abstract
Methods and kits for detecting polymorphisms that are predictive of a subject's susceptibility to developing an obstructive airway disease, such as asthma, as well as for determining the relative severity of the disease are described. Assays for identify therapeutics are also described.
Claims49
A method for determining whether a subject has or is predisposed to developing an obstructive airway disease (OAD), comprising the step of detecting in a nucleic acid sample from the subject, an OAD associated allele, which is selected from the group consisting of:
- allele 2 of IL-13 (+2581);
- allele 2 of IL-1B (−511);
- allele 2 of IL-1B (+3954);
- or an allele in linkage disequilibrium with allele 2 of IL-1B (−511) or allele 2 of IL-1B (+3954) selected from the group consisting of:
- allele 4 of IL-1A (222/223);
- allele 4 of IL-1A (gz5/gz6);
- allele 1 of IL-1A (−889);
- allele 1 of (+3954);
- allele 3 of the gaat.p33330 marker;
- allele 3 of the Y31 marker;
- allele 2 of IL-1RN (+2018);
- allele 2 of IL-1RN (VNTR);
- allele 3 of IL-1A (222/223);
- allele 3 of IL-1A (gz5/gz6);
- allele 2 of IL-1A (−889);
- allele 1 of IL-1B (−511);
- allele 4 of the gaat.p33330 marker;
- allele 6 of the Y31 marker;
- allele 1 of IL-1RN (+2018);
- and allele 1 of IL-1RN (VNTR), wherein detection of the obstructive airway disease associated allele indicates that the subject has or is predisposed to the development of an obstructive airway disease.
A kit for determining the existence of or a susceptibility to developing an obstructive airway disease (OAD) in a subject, said kit comprising a first primer oligonucleotide that hybridizes 5′ or 3′ to an allele selected from the group consisting of:
- allele 2 of IL-13 (+2581);
- allele 2 of IL-1B (−511);
- allele 2 of IL-1B (+3954);
- or an allele in linkage disequilibrium with allele 2 of IL-1B (−511) or allele 2 of IL-1B (+3954) selected from the group consisting of:
- allele 4 of IL-1A (222/223);
- allele 4 of IL-1A (gz5/gz6);
- allele 1 of IL-1A (−889);
- allele 1 of (+3954);
- allele 3 of the gaat.p33330 marker;
- allele 3 of the Y31 marker;
- allele 2 of IL-1RN (+2018);
- allele 2 of IL-1RN (VNTR);
- allele 3 of XL-1A (222/223);
- allele 3 of IL-1A (gz5/gz6);
- allele 2 of IL-1A (−889);
- allele 1 of IL-1B (−511);
- allele 4 of the gaat.p33330 marker;
- allele 6 of the Y31 marker;
- allele 1 of IL-1RN (+2018);
- and allele 1 of IL-1RN (VNTR).
A method for selecting an appropriate therapeutic for an individual that has or is predisposed to developing an obstructive airway disease (OAD), comprising the steps of:
- detecting whether the subject contains an OAD causative allele or an OAD associated allele that is associated with an OAD causative allele;
- and selecting a therapeutic that compensates for the OAD causative allele.
A method for treating or preventing the development of an OAD in a subject comprising the steps of detecting the presence of an OAD causative mutation or an OAD associated allele that is associated with an OAD causative mutation;
- and administering to the subject a therapeutic that compensates for the OAD causative mutation.
Dependencies are inferred from the claim text.